Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAMIU4)

• Drug Name: VIR-201 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMAMIU4

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon-gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emapalumab	DMZG5WL	Primary haemophagocytic lymphohistiocytosis	4A01.23	Approved	[3]
Fumaric acid	DMP83UZ	Multiple sclerosis	8A40	Phase 3	[4]
CIGB-128	DMB2MKU	Basal cell carcinoma	2C32	Phase 1	[5]
AMG 811	DMEIMBP	Discoid lupus erythematosus	EB51.0	Phase 1	[6]
CRx-191	DMB9QSJ	Psoriatic disorder	EA90	Discontinued in Phase 2	[7]
TAK-603	DMN1YHP	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[8]
Fontolizumab	DMEH6LV	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[9]
TG-1042	DMS4BUK	B-cell lymphoma	2A86	Discontinued in Phase 2	[10]
VPM-4-001	DMZHAVG	Prostate cancer	2C82.0	Preclinical	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-gamma (IFNG)	TT93WF5	IFNG_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010310)
• [2] EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
• [5] Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
• [6] Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
• [7] CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
• [8] T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
• [9] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [10] Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
• [11] BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.